From FNA To FNB And Next-Gen Smart EBUS-TBNA Needles

-How Manners' Platform Supports Product Iteration

https://profed.olympuschina.com/gs/thoracicsurgery/12628/

Early EBUS-TBNA primarily utilized Fine Needle Aspiration (FNA, 22G/25G) for cytology specimens. However, precision medicine demands histological subtyping and molecular testing, driving a trend towards larger-bore biopsy needles (Fine Needle Biopsy - FNB, 19G) and side-port/grooved needles (adapting concepts like ProCore). Concurrently, clinicians desire enhanced functionality: improved tissue retention (side-window designs), reduced tissue trauma (superelastic NiTi), and clearer ultrasound visualization throughout the procedure (advanced etching algorithms).

Manners' existing manufacturing platform is architected for future evolution:

• Large-Bore Tube Drawing & Back-Cut Optimization:​ Capabilities for 19G needle tubes (OD≈1.06mm) with maximized inner lumens while maintaining uniform wall thickness. Back-cut edge angles are optimized via FEA for piercing firmer lymph nodes, minimizing "needle skating."
• Nitinol Superelastic Shaft Production:​ Established heat treatment protocols and laser micro-machining databases support full-spectrum NiTi product development, paving the way for dedicated high-flexibility FNB needles.
• Advanced Etching Pattern Library:​ Expansion beyond simple helical grooves to segmented dense dot matrices, crisscross grids, etc., optimized for specific ultrasound frequencies (5–12MHz convex probes) to maximize backscatter. Prototypes explore weakened etching near the tip to aid depth perception.

Future Directions R&D:​ Concepts include integrated micro-force sensing feedback (piezoelectric films within the handle), coaxial injection/drainage multifunctionality (chemotherapy infusion, abscess drainage), and detachable tissue capture chambers-all built upon the same foundational platform of precision tubing, laser micro-machining, and electropolishing cleanliness.

For global brands and multinational OEMs, partnering with a manufacturer possessing platform-level precision machining capabilities and sustained R&D investment (like Manners) significantly shortens the time-to-market for next-generation EBUS-TBNA products. Together, we can advance respiratory interventional biopsy towards the paradigm of "more efficient tissue acquisition + safer real-time navigation."